Cargando…

Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™

OBJECTIVE: This study assessed treatment patterns, disease burden, outcomes, and unmet needs among patients with episodic migraine (EM) in China using Adelphi Migraine Disease Specific Programme™ (DSP) real-world data. BACKGROUND: Migraine is a prevalent and debilitating neurological disorder which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Hongru, Xiao, Zheman, Zhang, Lei, Ford, Janet, Zhong, Shiying, Ye, Wenyu, Li, Jinnan, Tockhorn-Heidenreich, Antje, Cotton, Sarah, Chen, Chunfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904300/ https://www.ncbi.nlm.nih.gov/pubmed/36762367 http://dx.doi.org/10.2147/JPR.S371887

Ejemplares similares

Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme
por: Ueda, Kaname, et al.
Publicado: (2019)

Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme
por: Hirata, Koichi, et al.
Publicado: (2020)

A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe
por: Ford, Janet H., et al.
Publicado: (2020)

Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures
por: Ford, Janet, et al.
Publicado: (2021)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China
por: Zhang, Lei, et al.
Publicado: (2023)

Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis
por: Holdsworth, Elizabeth A., et al.
Publicado: (2021)

Discrete Choice Experiment to Understand Japanese Patients’ and Physicians’ Preferences for Preventive Treatments for Migraine
por: Seo, Jaein, et al.
Publicado: (2023)

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
por: Citrome, Leslie, et al.
Publicado: (2021)

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
por: Ruff, D. D., et al.
Publicado: (2019)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study
por: Seo, Jaein, et al.
Publicado: (2021)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study
por: Okonkwo, Rose, et al.
Publicado: (2021)

Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
por: Ailani, Jessica, et al.
Publicado: (2022)

Editorial: Neurogenic inflammation in paroxysmal disorders (migraine and epilepsy)
por: Xiao, Zheman
Publicado: (2023)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

Pediatric migraine and episodic syndromes that may be associated with migraine
por: Spiri, Daniele, et al.
Publicado: (2014)

Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Interventional Procedures in Episodic Migraine
por: Plato, Brian M., et al.
Publicado: (2020)

Episodic Migraine and Older Adults
por: Riggins, Nina, et al.
Publicado: (2022)

Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine
por: Ford, Janet H., et al.
Publicado: (2023)

Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of Real-World Data
por: Hirata, Koichi, et al.
Publicado: (2020)

Temporal Patterns of Vertigo and Migraine in Vestibular Migraine
por: Yan, Manyun, et al.
Publicado: (2020)

Migraine with benign episodic unilateral mydriasis
por: Skeik, Nedaa, et al.
Publicado: (2011)

The acute and preventative treatment of episodic migraine
por: Miller, Sarah
Publicado: (2012)

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Sex and Gender Considerations in Episodic Migraine
por: Ahmad, Sarah R., et al.
Publicado: (2022)

A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment
por: Lombard, Louise, et al.
Publicado: (2020)

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
por: Reuter, Uwe, et al.
Publicado: (2021)

2-Deoxyglucose alleviates migraine-related behaviors by modulating microglial inflammatory factors in experimental model of migraine
por: Qiu, Tao, et al.
Publicado: (2023)

The borderland of migraine with aura: episodic unilateral mydriasis
por: Maggioni, F., et al.
Publicado: (2010)

Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
por: Fogang, Yannick Fogoum, et al.
Publicado: (2014)

Depression and risk of transformation of episodic to chronic migraine
por: Ashina, Sait, et al.
Publicado: (2012)

Alterations in pain processing circuitries in episodic migraine
por: Mungoven, Tiffani J., et al.
Publicado: (2022)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vaj7t53l9lr3cmrmnhogj44s7l